| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | TOBIRA THERAPEUTICS INC | 2,668,570 | 106,049,000 | 52.04% | ||
| 2 | COLLEGIUM PHARMACEUTICAL INC COM | 1,887,332 | 36,350,000 | 17.84% | ||
| 3 | AMICUS THERAPEUTICS INC COM | 2,600,014 | 19,240,000 | 9.44% | ||
| 4 | LION BIOTECHNOLOGIES INC COM | 2,087,281 | 17,178,000 | 8.43% | ||
| 5 | CIDARA THERAPEUTICS INC | 1,312,258 | 15,025,000 | 7.37% | ||
| 6 | IGNYTA INC COM | 950,366 | 5,978,000 | 2.93% | ||
| 7 | Sierra Oncology, Inc. | 2,186,195 | 3,979,000 | 1.95% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001420506-16-001352, filed 2016.11.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
